Health Condition 1: O- Medical and Surgical
Conditions
Interventions
Intervention1: sugammadex: patients will receive 2 mg/kg sugammadex IV at reappearance of second twitch(T2) of TOF before extubation
Control Intervention1: Neostigmine: patients will receive 0.05 mg/k
Sponsors
Dr Reshma salim
Eligibility
Inclusion criteria
Inclusion criteria: ASA I and III Subjects born in India, have never emigrated out of India and have an Indian home address. Patients undergoing elective surgical procedures under general anaesthesia Hemodynamically stable patients with all routine investigations within the normal limits. Patients who give informed written consent and are willing to be a part of the study
Exclusion criteria
Exclusion criteria: Age less than 18yrs and more than 65yrs ASA grading more than III Patients with anatomical malformations expected to lead to difficult tracheal intubation Known or suspected neuromuscular disorders affecting NMB Significant renal/hepatic dysfunction, (family) history of malignant hyperthermia, Allergy to general anaesthesia medications,contraindication to study drugs Medication known to interfere with NMBAs (such as anticonvulsants, aminoglycosides, and magnesium-containing medications) Patients Not Giving Consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To compare recovery from vecuronium-induced neuromuscular blockade with sugammadex to that with neostigmine/glycopyrrolate. (fast recover, patient responsiveness)Timepoint: 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate the side effects of a single dose of sugammadex 2 mg/kg to neostigmine 0.05mg/kg (plus glycopyrrolate) in adult patients Event of residual paralysis Total time spend in Operating room & PACU after extubation. Timepoint: 6 months | — |
Countries
India
Contacts
Public ContactDr Bhavini Shah
DR D Y PATIL MEDICAL COLLEGE, HOSPITAL AND RESEARCH CENTRE, PIMPRI , PUNE
Outcome results
None listed